<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04129320</url>
  </required_header>
  <id_info>
    <org_study_id>CP-MGA271-05</org_study_id>
    <nct_id>NCT04129320</nct_id>
  </id_info>
  <brief_title>Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck</brief_title>
  <official_title>A Phase 2/3 Open-Label Trial to Evaluate Enoblituzumab in Combination With MGA012 or MGD013 in the First-Line Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MacroGenics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MacroGenics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label study designed to evaluate safety and efficacy of enoblituzumab in&#xD;
      combination with MGA012 or MGD013 in first-line treatment of patients with recurrent or&#xD;
      metastatic squamous cell carcinoma of the head and neck (SCCHN).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will initially be conducted in 2 modules, Module X (enoblituzumab plus MGA012) and&#xD;
      Module Y (enoblituzumab plus MGD013). Enrollment into Modules X and Y, with approximately 30&#xD;
      patients each, will occur independently in a non-randomized fashion. Data from these modules&#xD;
      will determine if further evaluation will occur in randomized Module A (Phase 2) and&#xD;
      randomized Module B (Phase 3).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Change in study design&#xD;
  </why_stopped>
  <start_date type="Anticipated">October 2019</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel study model refers to concurrent enrollment of non-randomized Modules X and Y.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (Modules X and Y)</measure>
    <time_frame>2 years</time_frame>
    <description>Proportion of patients with best overall response of complete response (CR) plus partial response (PR) per RECIST 1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events as assessed by CTCAE v 4.03 (Modules X and Y)</measure>
    <time_frame>Up to 30 days after last dose of study drug</time_frame>
    <description>Evaluation of adverse events and serious adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival - (Modules X and Y)</measure>
    <time_frame>2 years</time_frame>
    <description>Time from start of study treatment to the first documented disease progression per RECIST v1.1 or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate - (Modules X and Y)</measure>
    <time_frame>2 years</time_frame>
    <description>Percentage of patients who experienced response of CR, PR or stable disease for at least 3 months from start of study treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response - (Modules X and Y)</measure>
    <time_frame>2 years</time_frame>
    <description>Time from the date of initial response to the date of first documented progression or death from any cause, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity (Module X)</measure>
    <time_frame>2 years</time_frame>
    <description>Percentage of patients developing anti-drug antibodies to enoblituzumab and/or MGA012</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity (Module Y)</measure>
    <time_frame>2 years</time_frame>
    <description>Percentage of patients developing anti-drug antibodies to enoblituzumab and/or MGD013</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (Module X)</measure>
    <time_frame>2 years</time_frame>
    <description>Maximum serum concentration of enoblituzumab and MGA012</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough (Module X)</measure>
    <time_frame>2 years</time_frame>
    <description>Trough serum concentration of enoblituzumab and MGA012</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (Module Y)</measure>
    <time_frame>2 years</time_frame>
    <description>Maximum serum concentration of enoblituzumab and MGD013</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough (Module Y)</measure>
    <time_frame>2 years</time_frame>
    <description>Trough serum concentration of enoblituzumab and MGD013</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Head and Neck Cancer</condition>
  <condition>Squamous Cell Carcinoma of Head and Neck</condition>
  <arm_group>
    <arm_group_label>Experimental Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enoblituzumab plus MGA012</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enoblituzumab plus MGD013</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>enoblituzumab</intervention_name>
    <description>anti-B7-H3 antibody</description>
    <arm_group_label>Experimental Arm 1</arm_group_label>
    <arm_group_label>Experimental Arm 2</arm_group_label>
    <other_name>MGA271</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MGA012</intervention_name>
    <description>anti-PD-1 antibody</description>
    <arm_group_label>Experimental Arm 1</arm_group_label>
    <other_name>INCMGA00012</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MGD013</intervention_name>
    <description>PD-1 X LAG-3 bispecific DART protein</description>
    <arm_group_label>Experimental Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven, recurrent or metastatic SCCHN not curable by local therapy&#xD;
&#xD;
          -  No prior systemic therapy for SCCHN in the recurrent or metastatic setting (with the&#xD;
             exception of systemic therapy completed &gt; 6 months prior of given as part of&#xD;
             multimodal treatment for locally advanced disease)&#xD;
&#xD;
          -  Primary tumor locations of oropharynx, oral cavity, hypopharynx, or larynx&#xD;
&#xD;
          -  At least one radiographically measurable lesion&#xD;
&#xD;
          -  HPV test results available (positive and negative eligible)&#xD;
&#xD;
          -  ECOG Performance status of 0 or 1&#xD;
&#xD;
          -  Adequate end organ function&#xD;
&#xD;
          -  Positive PD-L1 expression level (CPS â‰¥ 1%)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Disease suitable for local therapy administered with curative intent&#xD;
&#xD;
          -  Progressive disease within 6 months of completion of curatively intended systemic&#xD;
             treatment for locoregionally advanced SCCHN&#xD;
&#xD;
          -  Radiation or other non-systemic therapy within 2 weeks of first dose of study drug&#xD;
&#xD;
          -  Diagnosis of immunodeficiency, or use of immunosuppresive therapy within 14 days of&#xD;
             first dose of study drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernanda I Arnaldez, MD</last_name>
    <role>Study Director</role>
    <affiliation>MacroGenics</affiliation>
  </overall_official>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 14, 2019</study_first_submitted>
  <study_first_submitted_qc>October 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2019</study_first_posted>
  <last_update_submitted>October 9, 2020</last_update_submitted>
  <last_update_submitted_qc>October 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SCCHN</keyword>
  <keyword>head and neck</keyword>
  <keyword>oropharyngeal</keyword>
  <keyword>oral cavity</keyword>
  <keyword>hypopharyngeal</keyword>
  <keyword>laryngeal cancer</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>PD-1</keyword>
  <keyword>B7-H3</keyword>
  <keyword>LAG-3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

